Tomoyuki Otsuka1,2, Takashi Nojiri3,4, Seigo Minami5, Hiroshi Hosoda6, Muneyoshi Kuroyama1, Haruhiko Hirata1, Kaori Nakanishi7,8, Suguru Yamamoto5, Kiyoshi Komuta5, Kenji Kangawa3, Takashi Kijima9. 1. Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan. 2. Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan. 3. Department of Biochemistry, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. 4. Department of General Thoracic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan. 5. Department of Respiratory Medicine, Osaka Police Hospital, Osaka, Japan. 6. Department of Regenerative Medicine and Tissue Engineering, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan. 7. Health Care Center, Osaka University, Toyonaka, Japan. 8. Department of Respiratory Medicine, Kinki Central Hospital of the Mutual Aid Association of Public School Teachers, Itami, Japan. 9. Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan tkijima@imed3.med.osaka-u.ac.jp.
Abstract
AIM: To identify predictive markers for efficacy of combination bevacizumab and carboplatin-paclitaxel treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Twenty patients received carboplatin (area under the concentration-time curve (AUC) 6 mg/ml×min) and paclitaxel (200 mg/m2) with bevacizumab (15 mg/kg) on day 1 of a 21-day cycle. After four cycles of induction therapy, patients received bevacizumab maintenance therapy until disease progression or unacceptable toxicity occurred. Plasma and serum samples (baseline, day 8 and before cycle 2) were analyzed for natriuretic peptide content. RESULTS: Plasma brain natriuretic peptide (BNP) levels were significantly decreased at day 8 (20.1±4.0 pg/ml vs. 9.1±1.8 pg/ml, p=0.0002). Patients whose plasma BNP level was reduced to <50% of the baseline at day 8 had a longer progression-free survival (PFS) than those with a less decrease (9.73 versus 2.63 months, p=0.00013). In multivariate Cox analysis, decrease of plasma BNP concentration was associated with a longer PFS (p=0.0022). CONCLUSION: Decrease of plasma BNP concentration correlated with PFS after a treatment of combination bevacizumab plus carboplatin-paclitaxel. Copyright
AIM: To identify predictive markers for efficacy of combination bevacizumab and carboplatin-paclitaxel treatment in patients with advanced non-squamous non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Twenty patients received carboplatin (area under the concentration-time curve (AUC) 6 mg/ml×min) and paclitaxel (200 mg/m2) with bevacizumab (15 mg/kg) on day 1 of a 21-day cycle. After four cycles of induction therapy, patients received bevacizumab maintenance therapy until disease progression or unacceptable toxicity occurred. Plasma and serum samples (baseline, day 8 and before cycle 2) were analyzed for natriuretic peptide content. RESULTS: Plasma brain natriuretic peptide (BNP) levels were significantly decreased at day 8 (20.1±4.0 pg/ml vs. 9.1±1.8 pg/ml, p=0.0002). Patients whose plasma BNP level was reduced to <50% of the baseline at day 8 had a longer progression-free survival (PFS) than those with a less decrease (9.73 versus 2.63 months, p=0.00013). In multivariate Cox analysis, decrease of plasma BNP concentration was associated with a longer PFS (p=0.0022). CONCLUSION: Decrease of plasma BNP concentration correlated with PFS after a treatment of combination bevacizumab plus carboplatin-paclitaxel. Copyright
Authors: Georgia K Thomas; Cory R Trankle; Salvatore Carbone; Hayley Billingsley; Benjamin W Van Tassell; Ronald K Evans; Ryan Garten; Elisabeth Weiss; Antonio Abbate; Justin M Canada Journal: Lung Date: 2021-07-08 Impact factor: 3.777